Oppenheimer Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price objective decreased by research analysts at Oppenheimer from $12.00 to $7.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the health services provider’s stock. Oppenheimer’s price objective points to a potential upside of 36.19% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. Leerink Partners decreased their price objective on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a research report on Thursday, February 26th. Bank of America raised Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Thursday, February 26th. Barclays initiated coverage on Teladoc Health in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target for the company. Zacks Research lowered Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Finally, TD Cowen reduced their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Five investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.56.

Teladoc Health Price Performance

Shares of Teladoc Health stock opened at $5.14 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.77 and a quick ratio of 2.67. Teladoc Health has a one year low of $4.40 and a one year high of $9.90. The business’s 50 day simple moving average is $5.86 and its two-hundred day simple moving average is $7.16. The stock has a market capitalization of $916.98 million, a P/E ratio of -4.51 and a beta of 2.13.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The firm had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. The business’s quarterly revenue was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts forecast that Teladoc Health will post -1.16 EPS for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.58% of the company’s stock.

Institutional Trading of Teladoc Health

Several institutional investors have recently bought and sold shares of the company. Alpine Global Management LLC purchased a new stake in Teladoc Health during the 4th quarter valued at $187,000. Virtu Financial LLC purchased a new position in Teladoc Health in the 4th quarter worth about $854,000. Corient Private Wealth LLC lifted its stake in Teladoc Health by 236.6% during the 4th quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock valued at $264,000 after acquiring an additional 26,494 shares during the period. Mackenzie Financial Corp lifted its stake in Teladoc Health by 38.6% during the 4th quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock valued at $1,157,000 after acquiring an additional 46,090 shares during the period. Finally, Empowered Funds LLC boosted its holdings in shares of Teladoc Health by 1.9% during the 4th quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock valued at $5,196,000 after acquiring an additional 14,029 shares during the last quarter. 76.82% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Oppenheimer cut its price target but retained an “outperform” rating, now $7 (from $12). The continued outperform stance and remaining upside (~36% from current levels) can be viewed as supportive for the stock. Teladoc Health price target lowered by Oppenheimer
• Positive Sentiment: Management will present at the Barclays 28th Annual Global Healthcare Conference on March 10. Investor access to CEO remarks and Q&A could clarify 2026 guidance and strategy, which is typically positive for sentiment if management provides reassuring detail. Teladoc to Participate in Investor Conference
• Neutral Sentiment: Teladoc filed an inducement award for a new Chief Growth Officer — 57,034 RSUs plus performance stock units. This is a standard hiring incentive (some dilution risk) but not likely material to valuation absent other changes. Teladoc Employee Inducement Award
• Neutral Sentiment: Aggregated analyst coverage now averages to a “Hold” per a recent synopsis — suggests mixed sentiment among brokers and limited near-term analyst-driven upside until clearer fundamental improvements. Teladoc Receives Average Hold Rating
• Negative Sentiment: Citigroup lowered its price target from $9 to $6 and moved to a “neutral” rating — a downgrade in target that reduces analyst-implied upside and can pressure sentiment. Citigroup Lowers Price Target
• Negative Sentiment: A report flagged a Russell 1000 rebalancing/target cut impacting Teladoc, which can trigger index-related selling or reduced passive demand and weigh on near-term price action. Russell 1000 Drops on Target Cut

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.